The AGP & DTx Summit Reveals Digital Therapies Reducing HbA1c Levels for Diabetes Care
The successful completion of the fourth AGP & DTx Summit in May 2026 in Shenzhen, themed "Beyond Glucose," gathered experts and health professionals to discuss innovative ways to improve diabetes care through digital therapies. Co-hosted by SIBIONICS, this year's summit emphasized the importance of continuous glucose monitoring (CGM), not just as a tool for tracking blood sugar levels, but as a means to derive clinical insights that can lead to improved therapeutic decisions and behavioral changes.
According to Professor Andrej Janež from the International Consortium for AGP and DTx Research, over the past two years, the research fund has supported 20 trials across 14 countries, highlighting the value of CGM in understanding dietary habits and glycemic responses in special populations. These trials focus on the integration of artificial intelligence with CGM data to enhance clinical practices.
Professor Sofianos Andrikopoulos pointed out that digital therapies can amalgamate software-driven interventions, lifestyle recommendations, medication assistance, and comprehensive care models. The data presented at the summit revealed a significant average reduction in HbA1c levels by 0.54 percentage points due to these digital interventions, underlining their critical role in structured diabetes management.
Further insights on the clinical phenotype were provided by Professor Wei Qiang, who demonstrated how routine admission parameters combined with CGM and AGP data assist in identifying metabolic phenotypes and treatment responses in hospitalized Type 2 diabetes patients. This fusion of data aids in tailoring more individualized care strategies.
Professor Shannon Lin cautioned against relying solely on CGM data, suggesting that data-driven management is vital for optimizing diabetes control. The study findings indicate a growing interest among both clinicians and patients in employing AI technologies to predict and offer personalized glycemic management recommendations.
Additionally, Professor Xiao Luo shared his research emphasizing how combining CGM with other monitoring techniques could illuminate changes in blood sugar and ketone levels during fasting and feeding cycles, thereby facilitating metabolic intervention implementations.
Tom Vesely, a representative for patients living with Type 1 diabetes for nearly 40 years, conveyed a crucial message about CGM technology. He emphasized that while it's essential to monitor blood glucose changes, the ultimate goal is to enhance not just physiological measures but overall happiness in life.
These discussions signal a transformative shift in diabetes care—moving from the mere surveillance of blood sugar levels to making proactive changes aimed at improving patient outcomes. As we venture further into the realm of digital health interventions, the focus shifts to harnessing technology to foster better health and well-being, paving the way for next-level diabetes management strategies.
According to Professor Andrej Janež from the International Consortium for AGP and DTx Research, over the past two years, the research fund has supported 20 trials across 14 countries, highlighting the value of CGM in understanding dietary habits and glycemic responses in special populations. These trials focus on the integration of artificial intelligence with CGM data to enhance clinical practices.
Professor Sofianos Andrikopoulos pointed out that digital therapies can amalgamate software-driven interventions, lifestyle recommendations, medication assistance, and comprehensive care models. The data presented at the summit revealed a significant average reduction in HbA1c levels by 0.54 percentage points due to these digital interventions, underlining their critical role in structured diabetes management.
Further insights on the clinical phenotype were provided by Professor Wei Qiang, who demonstrated how routine admission parameters combined with CGM and AGP data assist in identifying metabolic phenotypes and treatment responses in hospitalized Type 2 diabetes patients. This fusion of data aids in tailoring more individualized care strategies.
Professor Shannon Lin cautioned against relying solely on CGM data, suggesting that data-driven management is vital for optimizing diabetes control. The study findings indicate a growing interest among both clinicians and patients in employing AI technologies to predict and offer personalized glycemic management recommendations.
Additionally, Professor Xiao Luo shared his research emphasizing how combining CGM with other monitoring techniques could illuminate changes in blood sugar and ketone levels during fasting and feeding cycles, thereby facilitating metabolic intervention implementations.
Tom Vesely, a representative for patients living with Type 1 diabetes for nearly 40 years, conveyed a crucial message about CGM technology. He emphasized that while it's essential to monitor blood glucose changes, the ultimate goal is to enhance not just physiological measures but overall happiness in life.
These discussions signal a transformative shift in diabetes care—moving from the mere surveillance of blood sugar levels to making proactive changes aimed at improving patient outcomes. As we venture further into the realm of digital health interventions, the focus shifts to harnessing technology to foster better health and well-being, paving the way for next-level diabetes management strategies.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.